Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MEETINGS - Conference entitled Blood Product Safety & Transmissible Spongiform Encephalopathies (US) February 2002:

This article was originally published in Clinica

Executive Summary

Cambridge Healthtech Institute's eighth annual Blood Product Safety & Transmissible Spongiform Encephalopathies conference will be held on February 4-7 2002 in Washington, DC. The first two days will focus on blood product safety and features lectures on implications of NAT testing for transfusion services, the EU system for licensing test kits, new therapeutic products and tissue safety regulations. The latter half of the event is dedicated to developments in diagnosing and screening for TSE, including cyclic amplification of protein misfolding. Both subjects are supported by poster displays and exhibits. Further information from Frederick Vargus on tel: +1 617 630 1300; fax: +1 617 630 1325; email: [email protected]

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT074293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel